UNSPSC 51422216: Triamcinolone hexacetonide

This classification denotes a therapeutic glucocorticoid with the molecular formula C30H41FO7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I7GT1U99Y9, chemically known as 9-fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone 21-(3,3-dimethylbutyrate) but more generally known as triamcinolone hexacetonide, which bears US NIH Compound Identifier 21826.

UNSPSC 51422216 Triamcinolone hexacetonide is a Commodity code that nominally covers a specific corticosteroid pharmaceutical product, yet the recent state and local activity tagged under it reflects procurement of emergency-response pharmaceuticals and harm-reduction systems rather than the steroid compound itself. State and local health agencies and counties use this code to source naloxone (opioid-reversal medication) and related drug-deactivation systems supporting community health and public-safety initiatives. The issuing bodies include county health departments and community health programs operating at the local level, with procurement structured as competitive bidding processes that require vendors to maintain standard compliance certifications including drug-free workplace documentation, E-Verify eligibility confirmation, and specified insurance coverages.

Seminole County, Florida posted an IFB (Solicitation Number IFB60459723LAS) in June 2026 seeking annual procurement of 1,900 units of naloxone and 800 safe drug-deactivation systems with quarterly deliveries to the Seminole County Community Health Building in Sanford. The contract runs two years with a one-year renewal option, awarded on a fixed-fee basis with all shipping and delivery costs included in vendor pricing. The procurement does not specify explicit set-aside or disadvantaged-enterprise designations but carries potential FEMA funding with attendant federal compliance requirements including Clean Air Act and Federal Water Pollution Control Act adherence. The source shows limited recent activity tagged under this code; the single opportunity identified reflects a mismatch between the code's nominal pharmaceutical scope and the actual procurement of naloxone and harm-reduction systems.